Literature DB >> 34413139

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.

Adrian Gervais1,2, Tom Le Voyer1,2, Jérémie Rosain1,2, Quentin Philippot1,2, Jérémy Manry1,2, Eleftherios Michailidis3, Hans-Heinrich Hoffmann3, Shohei Eto4, Marina Garcia-Prat5, Lucy Bizien1,2, Alba Parra-Martínez5, Rui Yang6, Liis Haljasmägi7, Mélanie Migaud1,2, Karita Särekannu7, Julia Maslovskaja7, Evangelos Vandreakos8, Olivier Hermine2,9, Aurora Pujol10, Pärt Peterson7, Trine H Mogensen11,12, Lee Rowen13, James Mond14, Xavier de Lamballerie15, Xavier Duval16,17,18,19, France Mentré16,17,18, Marie Zins20, Pere Soler-Palacin5, Roger Colobran21, Guy Gorochov22,23, Xavier Solanich24, Sophie Susen25, Javier Martinez-Picado26,27,28, Didier Raoult29,30, Marc Vasse31, Peter K Gregersen32, Lorenzo Piemonti33, Carlos Rodríguez-Gallego34,35, Luigi D Notarangelo36, Helen C Su36,37, Kai Kisand7, Satoshi Okada4, Anne Puel1,2,6, Emmanuelle Jouanguy1,2,6, Charles M Rice3, Pierre Tiberghien38,39, Qian Zhang1,2,6, Aurélie Cobat1,2,6, Laurent Abel1,2,6, Jean-Laurent Casanova40,2,6,41, Paul Bastard40,2,6, Nicolas de Prost42,43, Yacine Tandjaoui-Lambiotte44, Charles-Edouard Luyt45,46, Blanca Amador-Borrero47, Alexandre Gaudet48,49,50,51,52, Julien Poissy48,49,50,51,52, Pascal Morel38,39, Pascale Richard38, Fabrice Cognasse53,54, Jesus Troya55, Sophie Trouillet-Assant56, Alexandre Belot57,58, Kahina Saker57, Pierre Garçon59, Jacques G Rivière5, Jean-Christophe Lagier29,30, Stéphanie Gentile60,61, Lindsey B Rosen36, Elana Shaw36, Tomohiro Morio62, Junko Tanaka63, David Dalmau64, Pierre-Louis Tharaux65, Damien Sene47, Alain Stepanian66, Bruno Megarbane67, Vasiliki Triantafyllia68, Arnaud Fekkar1,69, James R Heath13, José Luis Franco70, Juan-Manuel Anaya71, Jordi Solé-Violán72,73, Luisa Imberti74, Andrea Biondi75, Paolo Bonfanti76, Riccardo Castagnoli36,77, Ottavia M Delmonte36, Yu Zhang36,78, Andrew L Snow79, Steven M Holland36, Catherine Biggs80, Marcela Moncada-Vélez6, Andrés Augusto Arias6,81,82, Lazaro Lorenzo1,2, Soraya Boucherit1,2, Boubacar Coulibaly1,2, Dany Anglicheau83, Anna M Planas84,85, Filomeen Haerynck86, Sotirija Duvlis87,88, Robert L Nussbaum89, Tayfun Ozcelik90, Sevgi Keles91, Ahmed A Bousfiha92, Jalila El Bakkouri92, Carolina Ramirez-Santana70,71, Stéphane Paul93, Qiang Pan-Hammarström94, Lennart Hammarström94, Annabelle Dupont25, Alina Kurolap95, Christine N Metz32, Alessandro Aiuti96, Giorgio Casari96, Vito Lampasona33, Fabio Ciceri97, Lucila A Barreiros98, Elena Dominguez-Garrido99, Mateus Vidigal100, Mayana Zatz100, Diederik van de Beek101, Sabina Sahanic102, Ivan Tancevski102, Yurii Stepanovskyy103, Oksana Boyarchuk104, Yoko Nukui105, Miyuki Tsumura4, Loreto Vidaur106,107, Stuart G Tangye108, Sonia Burrel109, Darragh Duffy110, Lluis Quintana-Murci111,112, Adam Klocperk113, Nelli Y Kann114, Anna Shcherbina114, Yu-Lung Lau115, Daniel Leung115, Matthieu Coulongeat116, Julien Marlet117,118, Rutger Koning101, Luis Felipe Reyes119,120, Angélique Chauvineau-Grenier121, Fabienne Venet122,123, Guillaume Monneret122,123, Michel C Nussenzweig124,41, Romain Arrestier42,43, Idris Boudhabhay83, Hagit Baris-Feldman95,125, David Hagin125,126, Joost Wauters127, Isabelle Meyts128,129, Adam H Dyer130, Sean P Kennelly130, Nollaig M Bourke131, Rabih Halwani132, Narjes Saheb Sharif-Askari132, Karim Dorgham22, Jérome Sallette133, Souad Mehlal Sedkaoui133, Suzan AlKhater134,135, Raúl Rigo-Bonnin136, Francisco Morandeira137, Lucie Roussel138,139, Donald C Vinh138,139, Sisse Rye Ostrowski140, Antonio Condino-Neto98, Carolina Prando141, Anastasiia Bonradenko103, András N Spaan6,142, Laurent Gilardin143,144, Jacques Fellay145,146,147, Stanislas Lyonnet148, Kaya Bilguvar149,150,151,152, Richard P Lifton149,150,153, Shrikant Mane150, Mark S Anderson154, Bertrand Boisson1,2,6, Vivien Béziat1,2, Shen-Ying Zhang1,2,6, Stéphanie Debette155,156.   

Abstract

Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases.
Copyright © 2021, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34413139      PMCID: PMC8521484          DOI: 10.1126/sciimmunol.abl4340

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  47 in total

1.  [Prevalence of autoantibodies in serum of healthy persons over 85 years of age].

Authors:  K Potocka-Płazak; A Pituch-Noworolska; J Kocemba
Journal:  Przegl Lek       Date:  1995

2.  A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.

Authors:  Lorena Sanchez-Felipe; Thomas Vercruysse; Sapna Sharma; Ji Ma; Viktor Lemmens; Dominique Van Looveren; Mahadesh Prasad Arkalagud Javarappa; Robbert Boudewijns; Bert Malengier-Devlies; Laurens Liesenborghs; Suzanne J F Kaptein; Carolien De Keyzer; Lindsey Bervoets; Sarah Debaveye; Madina Rasulova; Laura Seldeslachts; Li-Hsin Li; Sander Jansen; Michael Bright Yakass; Babs E Verstrepen; Kinga P Böszörményi; Gwendoline Kiemenyi-Kayere; Nikki van Driel; Osbourne Quaye; Xin Zhang; Sebastiaan Ter Horst; Niraj Mishra; Ward Deboutte; Jelle Matthijnssens; Lotte Coelmont; Corinne Vandermeulen; Elisabeth Heylen; Valentijn Vergote; Dominique Schols; Zhongde Wang; Willy Bogers; Thijs Kuiken; Ernst Verschoor; Christopher Cawthorne; Koen Van Laere; Ghislain Opdenakker; Greetje Vande Velde; Birgit Weynand; Dirk E Teuwen; Patrick Matthys; Johan Neyts; Hendrik Jan Thibaut; Kai Dallmeier
Journal:  Nature       Date:  2020-12-01       Impact factor: 49.962

3.  Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon.

Authors:  A Vallbracht; J Treuner; B Flehmig; K E Joester; D Niethammer
Journal:  Nature       Date:  1981-02-05       Impact factor: 49.962

4.  Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1.

Authors:  Christian Meisel; Bengisu Akbil; Tim Meyer; Erwin Lankes; Victor M Corman; Olga Staudacher; Nadine Unterwalder; Uwe Kölsch; Christian Drosten; Marcus A Mall; Tilmann Kallinich; Dirk Schnabel; Christine Goffinet; Horst von Bernuth
Journal:  J Clin Invest       Date:  2021-07-15       Impact factor: 14.808

5.  Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping.

Authors:  Iraldo Bello-Rivero; Majel Cervantes; Yeny Torres; Joel Ferrero; Eulises Rodríguez; Jesús Pérez; Idrian García; Gisou Díaz; Pedro López-Saura
Journal:  J Autoimmun       Date:  2004-08       Impact factor: 7.094

6.  Diverse functional autoantibodies in patients with COVID-19.

Authors:  Eric Y Wang; Tianyang Mao; Jon Klein; Yile Dai; John D Huck; Jillian R Jaycox; Feimei Liu; Ting Zhou; Benjamin Israelow; Patrick Wong; Andreas Coppi; Carolina Lucas; Julio Silva; Ji Eun Oh; Eric Song; Emily S Perotti; Neil S Zheng; Suzanne Fischer; Melissa Campbell; John B Fournier; Anne L Wyllie; Chantal B F Vogels; Isabel M Ott; Chaney C Kalinich; Mary E Petrone; Anne E Watkins; Charles Dela Cruz; Shelli F Farhadian; Wade L Schulz; Shuangge Ma; Nathan D Grubaugh; Albert I Ko; Akiko Iwasaki; Aaron M Ring
Journal:  Nature       Date:  2021-05-19       Impact factor: 49.962

7.  A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.

Authors:  Jean-Laurent Casanova; Helen C Su
Journal:  Cell       Date:  2020-05-13       Impact factor: 41.582

8.  Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.

Authors:  Jesús Troya; Aurora Pujol; Paul Bastard; Laura Planas-Serra; Pablo Ryan; Montse Ruiz; María de Carranza; Juan Torres; Amalia Martínez; Laurent Abel; Jean-Laurent Casanova
Journal:  J Clin Immunol       Date:  2021-04-13       Impact factor: 8.317

9.  SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.

Authors:  Peter Chen; Ajay Nirula; Barry Heller; Robert L Gottlieb; Joseph Boscia; Jason Morris; Gregory Huhn; Jose Cardona; Bharat Mocherla; Valentina Stosor; Imad Shawa; Andrew C Adams; Jacob Van Naarden; Kenneth L Custer; Lei Shen; Michael Durante; Gerard Oakley; Andrew E Schade; Janelle Sabo; Dipak R Patel; Paul Klekotka; Daniel M Skovronsky
Journal:  N Engl J Med       Date:  2020-10-28       Impact factor: 91.245

10.  Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.

Authors:  Nicolas de Prost; Paul Bastard; Romain Arrestier; Slim Fourati; Mathieu Mahévas; Sonia Burrel; Karim Dorgham; Guy Gorochov; Yacine Tandjaoui-Lambiotte; Iname Azzaoui; Ignacio Fernandes; Alain Combes; Jean-Laurent Casanova; Armand Mekontso-Dessap; Charles-Edouard Luyt
Journal:  J Clin Immunol       Date:  2021-02-22       Impact factor: 8.542

View more
  111 in total

1.  Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization.

Authors:  Giulia Lamacchia; Alessio Mazzoni; Michele Spinicci; Anna Vanni; Lorenzo Salvati; Benedetta Peruzzi; Sara Bencini; Manuela Capone; Alberto Carnasciali; Parham Farahvachi; Arianna Rocca; Seble Tekle Kiros; Lucia Graziani; Lorenzo Zammarchi; Jessica Mencarini; Maria Grazia Colao; Roberto Caporale; Francesco Liotta; Lorenzo Cosmi; Gian Maria Rossolini; Alessandro Bartoloni; Laura Maggi; Francesco Annunziato
Journal:  J Clin Immunol       Date:  2022-07-09       Impact factor: 8.317

2.  Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections.

Authors:  Allan Feng; Emily Yang; Andrew Moore; Shaurya Dhingra; Sarah Chang; Xihui Yin; Ruoxi Pi; Elisabeth Mack; Sara Völkel; Reinhard Geßner; Margrit Gundisch; Andreas Neubauer; Harald Renz; Sotirios Tsiodras; Paraskevi Fragkou; Adijat Asuni; Joseph Levitt; Jennifer Wilson; Michelle Leong; Jennifer Lumb; Rong Mao; Kassandra Pinedo; Jonasel Roque; Christopher Richards; Mikayla Stabile; Gayathri Swaminathan; Maria Salagianni; Vasiliki Triantafyllia; Wilhelm Bertrams; Catherine Blish; Jan Carette; Jennifer Frankovich; Eric Meffre; Kari C Nadeau; Upinder Singh; Taia Wang; Eline Luning Prak; Susanne Herold; Evangelos Andreakos; Bernd Schmeck; Chrysanthi Skevaki; Angela Rogers; Paul Utz
Journal:  Res Sq       Date:  2022-01-20

3.  Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq.

Authors:  Sara E Vazquez; Sabrina A Mann; Aaron Bodansky; Andrew F Kung; Zoe Quandt; Elise M N Ferré; Nils Landegren; Daniel Eriksson; Paul Bastard; Shen-Ying Zhang; Jamin Liu; Anthea Mitchell; Caleigh Mandel-Brehm; Brenda Miao; Gavin Sowa; Kelsey Zorn; Alice Y Chan; Chisato Shimizu; Adriana Tremoulet; Kara Lynch; Michael R Wilson; Olle Kampe; Kerry Dobbs; Ottavia M Delmonte; Luigi D Notarangelo; Jane C Burns; Jean-Laurent Casanova; Michail S Lionakis; Troy R Torgerson; Mark S Anderson; Joseph L DeRisi
Journal:  bioRxiv       Date:  2022-03-24

Review 4.  SARS-CoV-2 pathogenesis.

Authors:  Mart M Lamers; Bart L Haagmans
Journal:  Nat Rev Microbiol       Date:  2022-03-30       Impact factor: 60.633

Review 5.  The intersection of COVID-19 and autoimmunity.

Authors:  Jason S Knight; Roberto Caricchio; Jean-Laurent Casanova; Alexis J Combes; Betty Diamond; Sharon E Fox; David A Hanauer; Judith A James; Yogendra Kanthi; Virginia Ladd; Puja Mehta; Aaron M Ring; Ignacio Sanz; Carlo Selmi; Russell P Tracy; Paul J Utz; Catriona A Wagner; Julia Y Wang; William J McCune
Journal:  J Clin Invest       Date:  2021-12-15       Impact factor: 14.808

6.  Will GWAS eventually allow the identification of genomic biomarkers for COVID-19 severity and mortality?

Authors:  Vito Luigi Colona; Michela Biancolella; Antonio Novelli; Giuseppe Novelli
Journal:  J Clin Invest       Date:  2021-12-01       Impact factor: 14.808

7.  Abnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients.

Authors:  Dorothy L Butler; Luisa Imberti; Virginia Quaresima; Chiara Fiorini; Jeffrey C Gildersleeve
Journal:  PNAS Nexus       Date:  2022-06-17

Review 8.  The humoral response and antibodies against SARS-CoV-2 infection.

Authors:  Hai Qi; Linqi Zhang; Bo Liu; Xinquan Wang
Journal:  Nat Immunol       Date:  2022-06-27       Impact factor: 31.250

9.  Detection of Neutralizing Anti-Type 1 Interferon Autoantibodies.

Authors:  Elana R Shaw; Lindsey B Rosen; Li Ding; Steven M Holland; Helen C Su
Journal:  Curr Protoc       Date:  2022-08

10.  Clues that natural killer cells help to control COVID.

Authors:  Emilie Narni-Mancinelli; Eric Vivier
Journal:  Nature       Date:  2021-12       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.